Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial of Nivolumab and Ipilimumab in esophageal and gastroesophageal junction adenocarcinoma undergoing surgery is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2, Phase 3 | Status: SUSPENDED